Mode
Text Size
Log in / Sign up
N/A N=15 Randomized Basic Science

Effect of Peripheral Neuromodulation on Vaginal Blood Flow - Study 2

Female Sexual Dysfunction · Female Sexual Dysfunction Due to Physical Condition

Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: Maximum Percent Change in Vaginal Pulse Amplitude (VPA) From the Average Baseline Value — 119.8; 94.3; 135.4; 113.5 percent change of VPA

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Transcutaneous electrical nerve stimulation - Tibial Nerve (Device); Transcutaneous electrical nerve stimulation - Genital Nerve (Device); Neutral and Erotic Film Clip Alternation (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
University of Michigan
Primary completion
Jun 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Maximum Percent Change in Vaginal Pulse Amplitude (VPA) From the Average Baseline Value
119.8; 94.3; 135.4; 113.5; 9.9; 15.0
SECONDARY
Percent Change in Heart Rate From Baseline
2.4; 0.8; -0.5; 2.8; -2.8; 2.1
SECONDARY
Percent Change in Mean Arterial Blood Pressure From Baseline
1.8; 1.9; 2.1; 3.4; 0.3; 1.5
SECONDARY
Change in Subjective Arousal From Baseline
1.1; 1.4; 3.5; 3.4; 1.4; 1.6

Summary

The overall purpose of this research is to improve sexual function in women with sexual dysfunction. The goal of this study is to see if either of two nerve stimulation interventions cause a short-term change in vaginal blood flow. The effect of this intervention will be compared between women who have neurogenic (spinal cord injury) or non-neurogenic dysfunction and healthy women, to reveal mechanisms underlying neural control over vaginal blood flow.

Eligibility Criteria

Inclusion Criteria

All Participants

  • All participants will need internet access to complete the initial surveys and the diaries.

Non-dysfunction participants

  • Adult (over 18 years old) cis-gender female
  • Neurologically stable
  • Sexually active at least once per month
  • Able to understand consent and communicate effectively with research team

Non-SCI dysfunction participants

  • Adult (over 18 years old) cis-gender female
  • Neurologically stable
  • Sexually active at least once per month
  • Sexual dysfunction, per short-form Female Sexual Function Index (FSFI) score below 19
  • Lubrication difficulties, per short-form FSFI lubrication subdomain score below or equal to 3
  • Able to understand consent and communicate effectively with research team

Spinal cord injured participants

  • Adult (over 18 years old) cis-gender female
  • Clinically diagnosed spinal cord injury (Impairment score A-B) at vertebral level within C6-T10 at least six months prior or clinically diagnosed spinal cord injury (Impairment score C) at vertebral level within C4-T10 at least six months prior
  • Nominally sexually active, but at minimum interest in sexual pleasure even if fully self-induced
  • Sexual dysfunction, per short-form FSFI score below 19
  • Able to understand consent and communicate effectively with research team

Exclusion Criteria

Non-dysfunction participants:

  • Male
  • Pregnancy or planning to become pregnant during study period
  • Sexual dysfunction, per short-form FSFI score below 19
  • Lubrication difficulties, per short-form FSFI lubrication subdomain score below or equal to 4, or per investigator's discretion
  • Clinically diagnosed bladder dysfunction, pelvic pain, or other pelvic organ symptoms
  • Suspected or diagnosed epilepsy
  • Active infection or active pressure sores in the perineal region
  • Implanted pacemaker or defibrillator
  • Currently has or tested positive in the last 14 days for COVID-19 or is symptomatic for COVID-19

Non-SCI dysfunction participants:

  • Male
  • Pregnancy or planning to become pregnant during study period
  • Clinically diagnosed bladder dysfunction, pelvic pain, or other pelvic organ symptoms
  • Suspected or diagnosed epilepsy
  • Active infection or active pressure sores in the perineal region
  • Implanted pacemaker or defibrillator
  • Currently has or tested positive in the last 14 days for COVID-19 or is symptomatic for COVID-19

Spinal cord injured participants:

  • Male
  • Spinal cord injury at or above C5 level (C1-C5) if Impairment score A or B, or spinal cord injury at or above C3 level (C1-C3) if Impairment score C
  • Spinal cord injury below T10 vertebral level or reflexes not preserved
  • Acute worsening in motor or sensory function in the last month
  • Suspected or diagnosed epilepsy
  • Pregnancy or planning to become pregnant during study period
  • Active infection or active pressure sores in the perineal region
  • Implanted pacemaker or defibrillator
  • Currently has or tested positive in the last 14 days for COVID-19 or is symptomatic for COVID-19
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06999265). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search